期刊文献+

影响美托洛尔治疗效果的药物基因组学研究进展 被引量:4

Progress research on pharmacogenomics influencing curative effect of metoprolol
下载PDF
导出
摘要 药物临床反应个体差异与药物基因组学关系密切。研究证明,药物代谢酶、药物受体及其下游蛋白基因的遗传变异是造成药物反应个体差异的主要因素。美托洛尔作为治疗高血压及心血管疾病的经典药物被广泛应用于临床,但其安全范围窄,较易发生药物不良反应。近年研究发现,药物代谢酶CYP2D6、β1肾上腺受体蛋白以及G蛋白基因的遗传多态性是决定美托洛尔疗效个体差异的主要内在因素。本文作者对导致美托洛尔药物反应个体差异的相关基因的多态性及其对美托洛尔疗效的影响进行评述,以期为减少美托洛尔不良反应及提高临床疗效提供参考。
作者 李树春 王槐
出处 《吉林大学学报(医学版)》 CAS CSCD 北大核心 2013年第2期423-426,共4页 Journal of Jilin University:Medicine Edition
基金 国家自然科学基金资助课题(31100898) 中央高校基本科研业务费专项资金资助课题(0910KYQN68)
  • 相关文献

参考文献31

  • 1刘力生.中国高血压防治指南[M].3版.北京:人民卫生出版社,2010:12.
  • 2Walash MI,Belal FF,El-Enany NM,et al.Synchronousfluorescence spectrofluorimetric method for the simultaneousdetermination of metoprolol and felodipine in combinedpharmaceutical preparation[J].Chem Cent J,2011,5(1):70.
  • 3Evans WE,Relling MV.Pharmacogenomics:translatingfunctional genomics into rational therapeutics[J].Science,1999,286(5439):487-491.
  • 4Johnson JA,Zineh I,Puckett BJ.Beta 1-adrenergic receptorpolymorphisms and anti-hypertensive response tometoprolol[J].Clin Pharmacol Ther,2003,74(3):44-52.
  • 5Kyungsoo P,Seong BJ,Tae DK,et al.The effect of beta1-adrenergic receptor gene polymorphism on prolongation ofcorrected QT interval during endotracheal intubation undersevoflurane anesthesia[J].Korean J Anesthesiol,2011,61(2):117-121.
  • 6Mason DA,Moare JD,Green SA,et al.A gain-of-functionpolymorphism in a G-protien coupling domain of the humanbetal-adrenergic receptor[J].J Biol Chem,1999,274(18):12670-12674.
  • 7Liu J,Liu ZQ,Tan ZR,et al.Gly389Arg polymorphism ofbetal-adrenergic receptor is associated with the cardiovascularresponse to metoprolol[J].Clin Pharmacol Ther,2003,74(4):372-379.
  • 8Liu J,Liu ZQ,Yu BN,et al.Betal-Adrenergic receptorpolymorphisms influence the response to metoprololmonotherapy in patients with essential hypertension[J].ClinPharmacol Ther,2006,80(1):23-32.
  • 9Evans WE,Meleod HL.Pharmacogenomics-drug disposition,drug targets,and side effects[J].N Engl J Med,2003,348(6):538-549.
  • 10Holtbecker N,Fromm MF.Kroemer for induction of gut wallmetabolism[J].Drug Metab Dispos,1997,25(9):1107-1109.

二级参考文献113

共引文献45

同被引文献36

  • 1毕莹,罗明,徐远溪.心力衰竭患者β1肾上腺素受体多态性对美托洛尔治疗的影响[J].同济大学学报(医学版),2007,28(3):41-44. 被引量:1
  • 2Arjumand W, Abroad ST, Nafees S, et al. GNAS1 (Gcs) gene T393C polymorphism and Response to-Blockade, in a North Indian hypertension population: a case-control study [J]. Genet Test Mol Biomarkers, 2012, 16(9) : 1062-1066.
  • 3Minoretti P, Politi P, Coen E, et al. The T393C polymorphism of the GNAS1 gene is associated with deficit hypertension in an Italian population sample F J . Neurosci Lett, 2011,397 ( 1-2 ) : 159-163.
  • 4Abe M, Nakura J, Yamamoto M, et al. Association of GNASI gene variant with hypertension depending on smoking status [J]. Hypertension, 2012,40 ( 3 ) : 261-265.
  • 5Petersen M, Andersen JT, Hjelvang BR, et al. Association of GNASlpolymorphisms and mortality in calwedilol-treated chronicheart-failure patients [J]. Br J Clin Pharmacol, 2013,71 (4) :556-565.
  • 6Rau T, Dtingen HD, Edelmann F, et al. Impact of the ll- adrenoceptor Arg389Gly polymorphism on heart-rate responses to bisoprolol and carvedilol in heart-failure patients [J]. Clin Pharmacol Ther, 2012,92( 1 ) : 21-28.
  • 7Tesson F, Charron P, Peuchmaurd M, et al. Characteriza- tion of a unique genetic variant in the 1- adrenoceptor gene and evaluation of its role in idiopathic dilated cardiomyopathy [ - ] .Mol Cell Cardio1,2010,31 : 1025 - 1032.
  • 8Vesell ES. Advances in pharmacogenetics and pharmacog- enomics[ J] .Clin Pharmacol,2013,40:930- 938.
  • 9Cohn J N, Rector T S. Prognosis of congestive heart failure and predictors of mortality [ J ].Am Cardiol, 2013,62 : 25 - 30.
  • 10Toor D, Vohra H. Immune responsiveness during disease progression from acute rheumatic fever to chronic rheu- matic heart disease[J]. Microbes Infect, 2012,4 (12) : 1111 --1117.

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部